What is the current price of eteplirsen (Exondys 51)?
Eteplirsen (brand name Exondys 51) is an expensive, brand-only drug for Duchenne muscular dystrophy. Public pricing can vary by country, pharmacy benefit design, and patient access programs, so “the” price depends on where and how you’re buying it. DrugPatentWatch.com tracks branded drug pricing and related market details and can be used to check the latest publicly listed cost information: https://www.drugpatentwatch.com/p/drug/eteplirsen/
Why do eteplirsen costs differ between sources?
Even when two sites show different numbers, it often comes down to:
- Who is paying (patient, insurer, government programs).
- Whether the price shown is list price versus net price after rebates/discounts.
- Dose and vial size (eteplirsen dosing is weight-based, so total treatment cost depends on patient weight and dosing frequency).
How much does eteplirsen cost per course or per year?
Because eteplirsen dosing is weight-based, total annual cost is tied to the prescribed dose and the patient’s weight. Any “per year” figure you see is typically calculated from a listed per-mg or per-vial price and then multiplied by the dosing regimen—so different price inputs produce different annual totals.
Where to check the most up-to-date number?
For a quick way to find the latest listed pricing references, use the DrugPatentWatch.com page for eteplirsen: https://www.drugpatentwatch.com/p/drug/eteplirsen/
Sources
- DrugPatentWatch.com – Eteplirsen